The effectiveness of the mitochondrial-targeted drug dr20 for treatment of pulmonary hypertension, pulmonary fibrosis, and lung cancer.

TW202631152APending Publication Date: 2026-08-01KAOHSIUNG MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-11-06
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001071057_001
    Figure TWG2TA001071057_001
  • Figure TWG2TA001071057_002
    Figure TWG2TA001071057_002
  • Figure TWG2TA001071057_003
    Figure TWG2TA001071057_003
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceuticals, specifically to compounds, compositions, and their applications. The provided compounds effectively inhibit the pathological progression of diseases associated with mitochondrial dysfunction and promote the restoration of cellular function. Common mitochondrial dysfunction-related diseases include pulmonary arterial hypertension, pulmonary fibrosis, and non-small cell lung cancer.
Need to check novelty before this filing date? Find Prior Art